

## Diagnosis and Treatment of Alzheimer's Disease - Singapore Experience

Ng Kok Pin

Associate Professor

Alzheimer's disease (AD) is the most common cause of dementia and is characterized by core neuropathological features of amyloid plaques and neuro-fibrillary tangles that result in neurodegeneration, cognitive and behavioural manifestations.

Recently, the development of in-vivo biomarkers of AD has advanced the diagnosis of AD from a clinical syndrome to a biological construct. AT(N) is an unbiased descriptive classification scheme that groups amyloid plaques, neuro-fibrillary tau and neurodegeneration biomarkers that are available in AD research and clinical applications.

The FDA has recently granted accelerated or traditional approval of three monoclonal antibodies as treatments for AD. These three monoclonal antibodies are directed against specific forms of the amyloid- $\beta$  ( $A\beta$ ) peptide and have shown evidence of protein removal from the brain and slowing of cognitive and functional decline. Hence, this represents an advancement towards bringing disease-modifying treatments for AD into clinical practice.

This presentation will provide an update on the diagnosis and treatment of AD. The experience of diagnosing and treating AD in Singapore will also be shared in this presentation.

